UNSPSC 51112802: Idoxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C28H30INO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 456UXE9867, chemically known as pyrrolidine, 1-(2-(4-(1-(4-iodophenyl)-2-phenyl-1-butenyl)phenoxy)ethyl)-, (e)- but more generally known as idoxifene, which bears US NIH Compound Identifier 3034011. European Medicines Agency schedules Idoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08116MIG.

UNSPSC 51112802 Idoxifene is a Commodity code that covers procurement of this specific pharmaceutical product by state and local health agencies and benefit programs. State and local governments purchase idoxifene primarily through health and human services departments managing Medicaid, employee health plans, and pharmacy benefit programs. The code encompasses direct procurement pathways, including acquisition through traditional pharmacy benefit managers and group purchasing organizations, as well as emerging direct-to-manufacturer contracting models that state health agencies are beginning to explore to improve cost management and prescription fulfillment efficiency. State health and human services commissions are the primary issuing bodies under this code, with activity centered on managing pharmaceutical costs across employee health plans, Medicaid programs, and self-insured government benefit structures.

Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on April 3, 2026, soliciting vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks detailed information from potential vendors regarding their capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers, with particular focus on vendors' experience with direct contracting for self-insured employers and health plans within the past two years, flexibility to negotiate contracts based on net pricing models without rebates, and capability to implement value-based agreements. This exploratory procurement indicates that Texas is conducting foundational market intelligence to inform future formal solicitations and contracting strategy for direct-to-manufacturer pharmaceutical acquisition, though no award value, budget range, or set-aside designations are specified at this preliminary stage.